Affordable Access

deepdyve-link
Publisher Website

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

Authors
  • Oh, Yun
  • Herbst, Roy S
  • Burris, Howard
  • Cleverly, Ann
  • Musib, Luna
  • Lahn, Michael
  • Bepler, Gerold
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Mar 01, 2008
Volume
26
Issue
7
Pages
1135–1141
Identifiers
DOI: 10.1200/JCO.2007.14.3685
PMID: 18309949
Source
Medline
License
Unknown

Abstract

Although the primary end point of a 20% PFS rate was not achieved, 13% of the patients had PFS for >or= 6 months. Given the tolerability and survival data, evaluation of enzastaurin in combination with cytotoxic drugs is warranted in NSCLC.

Report this publication

Statistics

Seen <100 times